HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.

Abstract
It has been well established that chemo-immunotherapy using cytotoxic drugs and appropriate cytokines offers a new approach to increasing the therapeutic index in the treatment of neoplastic diseases. This study investigates the efficacy of combinations of interleukin-12 with cyclophosphamide, paclitaxel, cisplatin or doxorubicin in the murine L1210 leukemia model. Mice inoculated i.p. with 1 x 10(3) or 1 x 10(5) leukemia cells were treated with interleukin-12 and/or chemotherapeutics, and were observed daily for survival. Immunosuppression with X-irradiation or macrophage depletion with injections of silica were used to examine the dependence of the therapeutic effects on the efficiency of the immune system. Treatment with interleukin-12 or one of the studied chemotherapeutics given alone resulted in moderate antileukemic effects. Combination of interleukin-12 with cyclophosphamide or paclitaxel produced no augmentation of anti-leukemic effects in comparison with these agents given alone. Combination of interleukin-12 with cisplatin resulted in prolongation of the survival time; however, in the experiment with mice inoculated with 1 x 10(5) leukemia cells, no long-term survivors (>60 days) were observed; on the contrary, combination of interleukin-12 with doxorubicin resulted in 100% long-term survivors. This effect was completely abrogated either by X-irradiation of mice or by macrophage depletion. We also found that doxorubicin augments IL-12-stimulated production of interferon-gamma in vivo. Our observations demonstrating potentiation of the antileukemic effects of the IL-12 and doxorubicin combination suggest that the combined use of these 2 agents could be beneficial in leukemia therapy.
AuthorsR Zagozdzon, J Gołab, T Stokłosa, A Giermasz, D Nowicka, W Feleszko, W Lasek, M Jakóbisiak
JournalInternational journal of cancer (Int J Cancer) Vol. 77 Issue 5 Pg. 720-7 (Aug 31 1998) ISSN: 0020-7136 [Print] United States
PMID9688305 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Recombinant Proteins
  • Interleukin-12
  • Doxorubicin
  • Interferon-gamma
  • Cyclophosphamide
  • Paclitaxel
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use)
  • Cisplatin (therapeutic use)
  • Combined Modality Therapy
  • Cyclophosphamide (therapeutic use)
  • Doxorubicin (therapeutic use)
  • Female
  • Immunotherapy
  • Interferon-gamma (immunology)
  • Interleukin-12 (therapeutic use)
  • Leukemia L1210 (blood, immunology, therapy)
  • Macrophage Activation
  • Macrophages (drug effects, immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Paclitaxel (therapeutic use)
  • Recombinant Proteins (therapeutic use)
  • Survival Analysis
  • Time Factors
  • Whole-Body Irradiation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: